Skip to main content
Start triage

Start triage first, then route to emergency care.

Need urgent help? Start triage first, then route to emergency care.

Roxee Medication Guide

Fluoxetine

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Tablet (Chewable) Pegasus Laboratories, Inc. Official label facts Owner quick guide first

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Aug 6, 2026, 7:47 p.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Aug 6, 2026, 7:47 p.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Aug 6, 2026, 7:49 p.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Illustration placeholder
Fluoxetine

Fluoxetine

Drug type: Generic ingredient • Branded profile FDA branded products available

Both Tablet (Chewable) Rx required 100% reference complete

Species: Both

Manufacturer: Pegasus Laboratories, Inc.

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Fluoxetine

For the treatment of canine separation anxiety in conjunction with a behavior modification plan. Species commonly shown: Both, Dog.

Generic name
Fluoxetine
Brand names
Reconcile®, RECONCILE
Manufacturer
Pegasus Laboratories, Inc.
Species
Both, Dog
Dosage forms
Tablet (Chewable)
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Reconcile® RECONCILE
Dosage forms
Tablet (Chewable)

Indications / Uses

For the treatment of canine separation anxiety in conjunction with a behavior modification plan.

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Side Effects

Top reported reactions (openFDA): Vomiting, Lack of efficacy - NOS, Diarrhoea, Seizure NOS, Lethargy (see also Central nervous system depression in Neurological), Decreased appetite.

FAQ

Both, Dog

Yes. Roxee shows this as prescription-only.

Tablet (Chewable)

Related Conditions

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the treatment of canine separation anxiety in conjunction with a behavior modification plan.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • wobbly/unsteady walking (1 reports)
  • Drooling (1 reports)
  • Dehydration (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Fluoxetine; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2026-US-013796
Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 20 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2026-US-013796
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2026-US-013796
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Unsteady walking (ataxia) (1 reports), Drooling (1 reports), Dehydration (1 reports), Decreased mean corpuscular volume (1 reports), Decreased mean corpuscular haemoglobin concentration (1 reports)

Body systems represented Signal grouping

Digestive (4), Neurologic (1), Behavior (3), Other (24)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (19 reports), Cat (13 reports)

Breed metadata in reports Metadata only

Crossbred Canine/dog (2), Samoyed (1), Catahoula Leopard Dog (1), Coonhound (unspecified) (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Fluoxetine fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

wobbly/unsteady walking, Drooling, Dehydration

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Fluoxetine brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case USA-USFDACVM-2026-US-013796 · adverse_reaction · adverse reactions
  2. Contraindication source · fda_animal_drugs · warnings contraindications
  3. FDA application profile · official_label · quick facts
  4. Medication usage source · fda_animal_drugs · quick facts
  5. FOI · document · documents
  6. SPL · document · documents
  7. Structured Product Label · document · documents
  8. Structured Product Label · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 10:44 PM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • wobbly/unsteady walking
  • Drooling
  • Dehydration

Most reported reactions:

  • Unsteady walking (ataxia) (1 reports)
  • Drooling (1 reports)
  • Dehydration (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Dog
Indication / use
For the treatment of canine separation anxiety in conjunction with a behavior modification plan.
Form / route / dose
Form: Tablet (Chewable)
Route: Oral
Confirm product label and patient-specific plan.
Warnings
  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Pegasus Laboratories, Inc.
Form: Tablet (Chewable)
Identifiers:
NADA: 141272 NDC Package: 49427-340-44 NDC Package: 49427-340-57 NDC Package: 49427-341-44 NDC Package: 49427-341-57 NDC Package: 49427-342-44 NDC Package: 49427-342-57 NDC Package: 49427-343-44 NDC Package: 49427-343-57 NDC Product: 49427
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
25
Matching reports
25
Active filters
0
Reset
Showing up to 50 matching reports.

USA-USFDACVM-2026-US-014067

Received 2026-03-25 · MSK · MSK

Serious
Species
Dog
Breed
Crossbred Canine/dog
Size / weight
25-49 lb (18.144 Kilogram)
Age
4-7 years (7 Year)
Sex
Female Unknown
Region
USA
Reactions
Seizure NOSShakingIncreased salivationChattering of teeth
Body systems
NeurologicOtherDigestive
Outcomes
Ongoing

USA-USFDACVM-2026-US-013796

Received 2026-03-23 · MSK · MSK

Non-serious
Species
Dog
Breed
Samoyed
Size / weight
50-99 lb (30.391 Kilogram)
Age
8+ years (13 Year)
Sex
Female Unknown
Region
USA
Reactions
Limb weaknessMusculoskeletal disorder NOSAbnormal movement NOS
Body systems
Other
Outcomes
Recovered/Normal

USA-USFDACVM-2026-US-013538

Received 2026-03-17 · MSK · MSK

Non-serious
Species
Dog
Breed
Catahoula Leopard Dog
Size / weight
50-99 lb (34 Kilogram)
Age
1-3 years (3.5 Year)
Sex
Male Neutered
Region
USA
Reactions
Behavioural disorder NOSVocalisationGrowlingAgitation
Body systems
BehaviorOther
Outcomes
Ongoing

USA-USFDACVM-2026-US-012701

Received 2026-03-17 · MSK · MSK

Non-serious
Species
Dog
Breed
Coonhound (unspecified)
Size / weight
50-99 lb (36.696 Kilogram)
Age
4-7 years (7 Year)
Sex
Female Unknown
Region
USA
Reactions
Leukopenia NOSNeutropeniaElevated alanine aminotransferase (ALT)Elevated cholesterol (total)
Body systems
Other
Outcomes
Ongoing

USA-USFDACVM-2026-US-012963

Received 2026-03-16 · MSK · MSK

Serious
Species
Dog
Breed
Great Pyrenees
Size / weight
50-99 lb (40.37 Kilogram)
Age
8+ years (13 Year)
Sex
Male Unknown
Region
USA
Reactions
Vestibular disorder NOSAtaxiaNystagmusTympanic rupture
Body systems
OtherNeurologic
Outcomes
Ongoing

USA-USFDACVM-2026-US-013584

Received 2026-03-13 · MSK · MSK

Non-serious
Species
Dog
Breed
Crossbred Canine/dog
Size / weight
25-49 lb (15.876 Kilogram)
Age
8+ years (1 Year)
Sex
Female Neutered
Region
USA
Reactions
ItchingLicking
Body systems
Skin & allergyOther
Outcomes
Ongoing

USA-USFDACVM-2026-US-012599

Received 2026-03-12 · MSK · MSK

Serious
Species
Dog
Breed
Bulldog - English
Size / weight
50-99 lb (22.68 Kilogram)
Age
4-7 years (4 Year)
Sex
Female Neutered
Region
USA
Reactions
Head tremorFly biting behaviourLack of efficacy - NOSPolydipsiaPruritusPolyuriaPyodermaElevated blood urea nitrogen (BUN)Urinary tract infectionProteinuriaHaematuria
Body systems
NeurologicBehaviorEffectivenessOtherSkin & allergy
Outcomes
Outcome Unknown

USA-USFDACVM-2026-US-009160

Received 2026-02-24 · MSK · MSK

Serious
Species
Cat
Breed
Domestic Shorthair
Size / weight
10-24 lb (4.808 Kilogram)
Age
4-7 years (4 Year)
Sex
Male Neutered
Region
USA
Reactions
Head bobbingDroolingNot eatingElevated temperatureLethargy (see also Central nervous system depression in Neurological)Hiding
Body systems
OtherDigestiveNeurologic
Outcomes
Ongoing

USA-USFDACVM-2026-US-002536

Received 2026-01-19 · MSK · MSK

Non-serious
Species
Cat
Breed
Bengal
Size / weight
10-24 lb (5.171 Kilogram)
Age
8+ years (17 Year)
Sex
Male Neutered
Region
USA
Reactions
Partial lack of efficacy
Body systems
Effectiveness
Outcomes
Ongoing

USA-USFDACVM-2026-US-001275

Received 2026-01-19 · MSK · MSK

Serious
Species
Cat
Breed
Scottish Fold Longhair
Size / weight
Under 10 lb (3.13 Kilogram)
Age
8+ years (15 Year)
Sex
Female Unknown
Region
USA
Reactions
Decreased appetiteDiarrhoeaVomiting
Body systems
Digestive
Outcomes
Ongoing

USA-USFDACVM-2026-US-002679

Received 2026-01-16 · MSK · MSK

Non-serious
Species
Cat
Breed
Domestic Shorthair
Size / weight
10-24 lb (4.7 Kilogram)
Age
8+ years (1 Year)
Sex
Male Neutered
Region
USA
Reactions
Joint ligament disorder NOSLimb weakness
Body systems
Other
Outcomes
Ongoing

USA-USFDACVM-2025-US-075705

Received 2026-01-15 · MSK · MSK

Non-serious
Species
Cat
Breed
Cat (unknown)
Sex
Unknown Unknown
Region
USA
Reactions
No signIntentional misuseMedication error NOS
Body systems
Other
Outcomes
Recovered/Normal

USA-USFDACVM-2025-US-074927

Received 2025-12-17 · MSK · MSK

Serious
Species
Dog
Breed
['Shepherd Dog - Australian', 'Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog)']
Size / weight
25-49 lb (14.969 Kilogram)
Age
4-7 years (5 Year)
Sex
Male Neutered
Region
USA
Reactions
AnxietyClenched jawShakingLoss of voluntary movementStiffness limbFallingBumping into wallsVomitingDehydrationHyperglycaemiaOther abnormal test result NOSLethargy (see also Central nervous system depression in Neurological)Abnormal tail postureStranguriaHaematuria
Body systems
BehaviorOtherDigestiveNeurologic
Outcomes
Outcome Unknown

USA-USFDACVM-2025-US-074596

Received 2025-12-16 · MSK · MSK

Serious
Species
Cat
Breed
Domestic Shorthair
Size / weight
Under 10 lb (3.18 Kilogram)
Age
8+ years (1 Year)
Sex
Female Unknown
Region
USA
Reactions
Lack of efficacy (bacteria) - NOSUpper respiratory soundsOcular dischargePeriorbital oedemaVasculitisSkin discolouration NOSFlaking skinSkin disorders NOS
Body systems
EffectivenessOther
Outcomes
Ongoing

USA-USFDACVM-2025-US-073869

Received 2025-12-16 · MSK · MSK

Non-serious
Species
Dog
Breed
Chihuahua
Size / weight
10-24 lb (7.7 Kilogram)
Age
4-7 years (6 Year)
Sex
Male Neutered
Region
USA
Reactions
Decreased urine concentrationProteinuriaInappropriate urinationWeight loss
Body systems
Other
Outcomes
Ongoing

USA-USFDACVM-2025-US-072759

Received 2025-12-15 · MSK · MSK

Serious
Species
Dog
Breed
Weimaraner
Size / weight
50-99 lb (34.019 Kilogram)
Age
8+ years (12 Year)
Sex
Female Unknown
Region
USA
Reactions
RecumbencyLimb weaknessReduced reflexesProprioception deficitHind limb paresis
Body systems
Other
Outcomes
Ongoing

USA-USFDACVM-2025-US-075469

Received 2025-12-12 · MSK · MSK

Non-serious
Species
Cat
Breed
Domestic Shorthair
Size / weight
Under 10 lb (3.175 Kilogram)
Age
8+ years (9 Year)
Sex
Female Neutered
Region
USA
Reactions
Administration error NOSLack of efficacy - NOSIntentional misuse
Body systems
OtherEffectiveness
Outcomes
Outcome Unknown

USA-USFDACVM-2025-US-072784

Received 2025-12-11 · MSK · MSK

Serious
Species
Dog
Breed
Mountain Dog - Bernese
Size / weight
50-99 lb (28.576 Kilogram)
Age
1-3 years (3 Year)
Sex
Female Unknown
Region
USA
Reactions
Seizure NOS
Body systems
Neurologic
Outcomes
Recovered/Normal

USA-USFDACVM-2025-US-072866

Received 2025-12-09 · MSK · MSK

Non-serious
Species
Dog
Breed
['Terrier (unspecified)', 'Dog (unknown)']
Size / weight
10-24 lb (5.262 Kilogram)
Age
4-7 years (7 Year)
Sex
Female Unknown
Region
USA
Reactions
Vomiting
Body systems
Digestive
Outcomes
Recovered/Normal

USA-USFDACVM-2025-US-072729

Received 2025-12-05 · MSK · MSK

Non-serious
Species
Dog
Breed
Terrier - Bull
Size / weight
25-49 lb (17.6 Kilogram)
Age
4-7 years (7 Year)
Sex
Female Neutered
Region
USA
Reactions
Leucopenia NOSAnaemia NOSHypoalbuminaemiaNeutropeniaPyodermaReduced globulinsHypophosphataemiaNon-regenerative anaemiaLow serum alkaline phosphatase (ALP)Pale mucous membraneElevated alanine aminotransferase (ALT)Decreased packed cell volume (PCV)Lethargy (see also Central nervous system depression in Neurological)HypocalcaemiaElevated aspartate aminotransferase (AST)HypoproteinaemiaProteinuriaElectrolyte disorderDisorder of red blood cell NOSElevated creatine-kinase (CK)Other coagulation investigation abnormalityIncreased band neutrophiliaElevated mean corpuscular volume (MCV)LymphopeniaOther abnormal test result NOSDiarrhoeaPanleucopeniaEosinopeniaDecreased haematocritIncreased percentage reticulocytes
Body systems
OtherNeurologicDigestive
Outcomes
Ongoing

USA-USFDACVM-2025-US-071530

Received 2025-12-03 · MSK · MSK

Serious
Species
Dog
Breed
Retriever - Labrador
Size / weight
50-99 lb (36.3 Kilogram)
Age
4-7 years (7 Year)
Sex
Male Intact
Region
USA
Reactions
Seizure NOS
Body systems
Neurologic
Outcomes
Recovered/Normal

USA-USFDACVM-2025-US-072107

Received 2025-12-01 · MSK · MSK

Serious
Species
Dog
Breed
Shepherd Dog - German
Size / weight
50-99 lb (40.1 Kilogram)
Age
8+ years (10.5 Year)
Sex
Male Neutered
Region
USA
Reactions
VocalisationAbnormal tail posturePain NOSWeight lossDecreased appetiteVomitingChewing disorderPantingTremblingLying downAnxietyExcessive chewing, licking and/or groomingMuscle atrophy (see also Muscle wasting)Musculoskeletal disorder NOSAbnormal radiograph findingSpondylosisJoint effusionElevated gamma-glutamyl transferase (GGT)LymphopeniaLethargy (see also Central nervous system depression in Neurological)Thoracic painDeath by euthanasiaMedication error NOS
Body systems
OtherDigestiveBehaviorNeurologic
Outcomes
Euthanized

USA-USFDACVM-2025-US-071839

Received 2025-11-28 · MSK · MSK

Serious
Species
Cat
Breed
Domestic Shorthair
Size / weight
10-24 lb (7.257 Kilogram)
Age
1-3 years (2 Year)
Sex
Male Neutered
Region
USA
Reactions
Lethargy (see also Central nervous system depression in Neurological)Stumbling gaitNot eatingNot drinkingCold feeling to the touchWobblinessNot urinatingUncomfortableFeverWeak pulseStiffness limbDecreased haematocritDecreased haemoglobinDecreased mean corpuscular volume (MCV)Decreased mean corpuscular haemoglobin concentration (MCHC)Red blood cell disorderHyperglycaemiaLow blood urea nitrogen (BUN)Low pancreatic enzymesUnable to walkEosinopenia
Body systems
NeurologicOther
Outcomes
Ongoing

USA-USFDACVM-2025-US-068770

Received 2025-11-21 · MSK · MSK

Non-serious
Species
Cat
Breed
Maine Coon
Size / weight
10-24 lb (10.43 Kilogram)
Age
1-3 years (3 Year)
Sex
Male Neutered
Region
USA
Reactions
Weight lossNystagmusThird eyelid protrusionLimb weaknessAtaxia
Body systems
OtherNeurologic
Outcomes
Ongoing

USA-USFDACVM-2025-US-071047

Received 2025-11-18 · MSK · MSK

Non-serious
Species
Cat
Breed
Domestic Shorthair
Size / weight
10-24 lb (5.443 Kilogram)
Age
4-7 years (4 Year)
Sex
Female Neutered
Region
USA
Reactions
Administration error NOSBehavioural disorder NOSStaringIntentional misuse
Body systems
OtherBehavior
Outcomes
Recovered/Normal

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
20
Species represented
2
Grouped by Body System
Digestive (4) · Drooling, Diarrhea, Decreased appetite Neurologic (1) · Unsteady walking (ataxia) Behavior (3) · Circling - behavioural disorder, Behavioral disorder (unspecified), Anxiety Other (24) · Elevated alanine aminotransferase, Electrolyte disorder, Disorder of red blood cell NOS
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Dog 1
Digestive 1 Cat 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Digestive 1 Cat 1

Species coverage: Dog (19) Cat (13)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Digestive Cat Serious - 1
Other Dog Non-serious - 1
Digestive Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Digestive Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Behavior Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Behavior Cat Non-serious - 1
Digestive Dog Non-serious - 1
Behavior Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Source metadata:

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

5

FOI

1

Reconcile®

SPL · SPL

FDA Structured Product Label

Reconcile®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Pegasus Laboratories, Inc.
NADA
141-272
Status
RX
Form
Tablet (Chewable)
Route
Oral
Species
Dog
Composition / specifications
Each chewable tablet contains 8, 16, 32, or 64 milligrams (mg) fluoxetine hydrochloride.

Dogs

Indication
For the treatment of canine separation anxiety in conjunction with a behavior modification plan.
Dosage
1 to 2 mg/kg body weight (0.5-0.9 mg/lb) once daily.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

RECONCILE SPL

SPL · Structured Product Label

FDA Structured Product Label XML for RECONCILE. Use the source link for the full official labeling record.

RECONCILE SPL

SPL · Structured Product Label

FDA Structured Product Label XML for RECONCILE. Use the source link for the full official labeling record.

RECONCILE SPL

SPL · Structured Product Label

FDA Structured Product Label XML for RECONCILE. Use the source link for the full official labeling record.

RECONCILE SPL

SPL · Structured Product Label

FDA Structured Product Label XML for RECONCILE. Use the source link for the full official labeling record.

ucm062326.pdf

FOI · FOI

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: RECONCILE
Manufacturer mapping: Pegasus Laboratories, Inc.
Case-reported brands (openFDA): MSK
Catalog species: Both FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Tablet (Chewable) Oral
Applications: NADA 141-272
NDC: Packages 49427-340-44 49427-340-57 49427-341-44 49427-341-57 49427-342-44 49427-342-57 Products 49427
Documents: 1 (FOI: 1) • SPL: 1 Label highlights Official documents
Safety (openFDA)
Top reactions: Dog 91 Cat 50 View
Case summaries: 25 (showing 8) View
openFDA reports are unverified and do not prove causation.

Explore
Related conditions: Separation anxiety
Linked using: Fda_Label (0.95)

Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Unsteady walking (ataxia) (1) Drooling (1) Dehydration (1) Decreased mean corpuscular volume (1) Decreased mean corpuscular haemoglobin concentration (1) Decreased haemoglobin (1) Decreased haematocrit (1) Decreased appetite (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141272 NDC Package: 49427-340-44 NDC Package: 49427-340-57 NDC Package: 49427-341-44 NDC Package: 49427-341-57 NDC Package: 49427-342-44 NDC Package: 49427-342-57 NDC Package: 49427-343-44 NDC Package: 49427-343-57 NDC Product: 49427
Package NDC Product NDC Form / Route Status
49427-340-44 49427 -
49427-340-57 49427 -
49427-341-44 49427 -
49427-341-57 49427 -
49427-342-44 49427 -
49427-342-57 49427 -
49427-343-44 49427 -
49427-343-57 49427 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • RECONCILE SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • RECONCILE SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • RECONCILE SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • RECONCILE SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • ucm062326.pdf • FOI summary • Official • Jan. 30, 2017
    FDA FOI summary for application 141272

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 124 Clinical 1 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Vomiting, Lack of efficacy - NOS, Diarrhoea, Seizure NOS, Lethargy (see also Central nervous system depression in Neurologica… (Clinical, 2026-04-11)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Official, 2026-04-12)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Official, 2026-04-11)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Official, 2026-02-12)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-08-06)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-08-05)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-08-04)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-08-03)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-08-02)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-08-01)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-07-31)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-07-30)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-07-29)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-07-28)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-07-27)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-07-26)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-07-25)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-07-25)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-07-22)
  • indications: RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. (Official, 2026-07-22)
Recent Revisions
  • side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Reconcile®
RX
Fluoxetine hydrochloride
Tablet (Chewable) Oral
Pegasus Laboratories, Inc. NADA 141-272 Approved Jan 30, 2017

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog
Composition / specifications
Each chewable tablet contains 8, 16, 32, or 64 milligrams (mg) fluoxetine hydrochloride.
Dogs
Indication
For the treatment of canine separation anxiety in conjunction with a behavior modification plan.
Dosage
1 to 2 mg/kg body weight (0.5-0.9 mg/lb) once daily.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Usage

For the treatment of canine separation anxiety in conjunction with a behavior modification plan.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Drooling (1) • Cat Diarrhea (1) • Dog Decreased appetite (1) • Cat Appetite loss (1) • Dog

Showing top 5 for Digestive.

Neurologic
Unsteady walking (1) • Dog

Showing top 5 for Neurologic.

Behavior
Circling - behavioural disorder (1) • Cat Behavioral disorder (1) • Cat Anxiety (1) • Dog

Showing top 5 for Behavior.

Other
Elevated alanine aminotransferase (1) • Dog Electrolyte disorder (1) • Dog Disorder of red blood cell NOS (1) • Dog Dehydration (1) • Dog Decreased urine concentration (1) • Dog
Show more (19)
Decreased packed cell volume (1) • Dog Decreased mean corpuscular volume (1) • Cat Decreased mean corpuscular haemoglobin concentration (1) • Cat Decreased haemoglobin (1) • Cat Decreased haematocrit (1) • Cat Death by euthanasia (1) • Dog Death (1) • Cat Cold feeling to the touch (1) • Cat Clenched jaw (1) • Dog Chewing disorder (1) • Dog Chattering of teeth (1) • Dog Calculi (1) • Cat Bumping into walls (1) • Dog Anaemia NOS (1) • Dog Agitation (1) • Dog Administration error NOS (1) • Cat Abnormal tail posture (1) • Dog Abnormal radiograph finding (1) • Cat Abnormal movement NOS (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Crossbred Canine/dog, Female, 7 year, 18.144 kilogram • Drug: MSK, Unassigned, Oral, Dose: 16 Milligram per animal, Frequency: 1 per day • Reactions: Seizure NOS, Shaking, Increased salivation, Chattering of teeth • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-014067
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 7.00 Year
  • Weight: 18.144 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Unassigned
  • Dose: 16 Milligram per animal
  • Frequency: 1 per day
Reactions Reported:
Seizure NOS Shaking Increased salivation Chattering of teeth
Outcomes: Ongoing

Dog, Samoyed, Female, 13 year, 30.391 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Limb weakness, Musculoskeletal disorder NOS, Abnormal movement NOS • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2026-US-013796
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 13.00 Year
  • Weight: 30.391 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Limb weakness Musculoskeletal disorder NOS Abnormal movement NOS
Outcomes: Recovered/Normal

Dog, Catahoula Leopard Dog, Male, 3.5 year, 34 kilogram • Drug: MSK, Tablet, Oral, Dose: 20 Milligram per animal • Reactions: Behavioral disorder (unspecified), Vocalisation, Growling, Agitation • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-013538
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 3.50 Year
  • Weight: 34.000 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 20 Milligram per animal
Reactions Reported:
Behavioral disorder (unspecified) Vocalisation Growling Agitation
Outcomes: Ongoing

Dog, Coonhound (unspecified), Female, 7 year, 36.696 kilogram • Drug: MSK, Unassigned, Oral • Reactions: Leukopenia NOS, Neutropenia, Elevated alanine aminotransferase, Elevated cholesterol • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-012701
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 7.00 Year
  • Weight: 36.696 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Unassigned
Reactions Reported:
Leukopenia NOS Neutropenia Elevated alanine aminotransferase Elevated cholesterol
Outcomes: Ongoing

Dog, Great Pyrenees, Male, 13 year, 40.37 kilogram • Drug: MSK, Unassigned, Oral, Dose: 40 Milligram per animal, Frequency: 24 per hour • Reactions: Vestibular disorder NOS, Unsteady walking (ataxia), Nystagmus, Tympanic rupture • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-012963
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 13.00 Year
  • Weight: 40.370 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Unassigned
  • Dose: 40 Milligram per animal
  • Frequency: 24 per hour
Reactions Reported:
Vestibular disorder NOS Unsteady walking (ataxia) Nystagmus Tympanic rupture
Outcomes: Ongoing

Dog, Crossbred Canine/dog, Female, 10 year, 15.876 kilogram • Drug: MSK, Unknown • Reactions: Itching, Licking • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-013584
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 10.00 Year
  • Weight: 15.876 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Itching Licking
Outcomes: Ongoing

Dog, Bulldog - English, Female, 4 year, 22.68 kilogram • Drug: MSK, Unknown • Reactions: Head tremor, Fly biting behaviour, Lack of efficacy - NOS, Polydipsia, Itching… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2026-US-012599
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Female
  • Age: 4.00 Year
  • Weight: 22.680 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Head tremor Fly biting behaviour Lack of efficacy - NOS Polydipsia Itching Polyuria Pyoderma Elevated blood urea nitrogen Urinary tract infection Proteinuria Haematuria
Outcomes: Outcome Unknown

Cat, Domestic Shorthair, Male, 4 year, 4.808 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Head bobbing, Drooling, Not eating, Elevated temperature, Tiredness (lethargy)… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-009160
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 4.00 Year
  • Weight: 4.808 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Head bobbing Drooling Not eating Elevated temperature Tiredness (lethargy) Hiding
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.